http://www.envita.com/conditions-we-treat/cancer/stage-4cancer/ - Stage 4 Cancer is also known as Stage IV Cancer, which spread to various sites in the body. It is a complex type of cancer to treat, and it can involve many organ systems. Envita’s vast area of technologies options gives stage 4 cancer patients the most complete approach to their cancer.

1. Relevant Stage 4 Cancer Solutions
As technology and our knowledge base continues to grow, it becomes more important
than ever to learn what is present in the realm of modern-day cancer treatments – in
particular, the availability of new techniques to deal with advanced and stage 4 cancer.
An article on the United States’ website HealthReport.gov explains, "Nearly one out of
two Americans born today will be diagnosed with cancer at some point in their lifetime."
Moreover, “About 1,596,670 new cancer cases are expected to be diagnosed in 2011 -
about 571,950 Americans are expected to die of cancer, more than 1,500 people a day
– and cancer is the second most common cause of death in the US, exceeded only by
heart disease. In the US, cancer alone accounts for nearly 1 of every 4 deaths," reports
the *American Cancer Society.
Amid these turbulent seas, there is a powerful treatment with which to approach stage 4
cancer called anti-angiogenic therapy. It works by starving the cancer cells from
nutrients, thereby impeding its growth and spread.
It is reported that nearly 90 percent of cancer patients succumb when their cancer
metastasizes – the calling card of stage 4 cancer. Angiogenesis is the process by
which tumors grow by attracting blood vessels to “nourish” themselves. However, a
technique exists to thwart these very processes. With newly developed modern

2. “alternative” medicines, both metastasis and angiogenesis can be impeded or even
subjugated.
Envita leads the domestic pack by currently offering such integrative and unique
processes. There is no denying that patients benefit from an anti-angiogenic approach
to supplement most traditional chemotherapy regimes. Through rigorous tests and
analysis, Envita recommends and implements strategies that will work synergistically
with the body to enhance the ultimate goal of patient health and well-being.
With these great developments, it is important to give credit where credit is due. The
origin of this research field began with Judah Folkman, who realized that a tumor placed
in a lab container had only a limited potential for growth, establishing that its micro
vascular network was being disrupted.
In the early days of his papers, 1964 to 1989, his findings were largely overlooked by
many. While they agreed that there was evidence of newly forming vessels, the
assumption was that the smaller, weaker cell networks were merely a side effect
associated with the dying tumor cells. Eventually, Folkman could prove that the new
vessels were actually being fashioned by the cancer cells themselves as a means of
supplemental nourishment.
In hindsight, it is something of an embarrassment that Dr. Folkman was treated the way
he was in the early days of his findings. In an industry so overcome by a poor track-
record, one would think that innovators, free thinkers, and pioneers would be eagerly
welcomed to the table. Unfortunately, cancer research, like so many other fields, seems
to harbor the same common pattern of contempt for the new and unknown.
Another such example of this contemptuous foolery came when Don Ingber found that a
fungus contaminated some of his endothelial cell test samples, which caused their
growth to cease. Of course, Inber was ignored and treated like a quack, until later it was
proven that angiogenesis could, in fact, be inhibited.
Today, anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®),
pazopanib (Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage
cancers in order to impeded growth. That being said, a simple agent like oxygen (not
patentable) is an oft overlooked. To put it mildly, oxygen is nothing less than a dominant
anti-angiogenic agent. Oxygen becomes an important agent for stage 4 cancer
treatment.
In fact, errors occurring in oxygen metabolism are often at the root of cancer causes as
well as their continued development. Moreover, understanding the role of oxygen and
correctly administering it can be vital for success in stage 4 cancer cases.

3. It is no secret that cancer cells rely upon a blood supply to spread. So, it stands to
reason that angiogenesis should be blocked to stop tumor growth. Virtually, all tumors
demand an unending supply of nutrients supplied via blood to continue to spread.
Without such supplies, tumor growth is limited to a manageable 2 mm.
In stage 4 cancer cases, it is a lack of oxygen that ultimately feeds growth and spread.
The introduction of vascular endothelial growth factor (VEGF) to angiogenesis, a critical
process, actually occurs because of hypoxia – the absence of oxygen. Transcriptional
factor HIF-1 (hypoxia inducible factor 1) allows this process to materialize.
There is always a need for hypoxic tissue on tumors to promote the release of VEGF -
as they invariably aim to grow beyond the limits of the blood supply. Should we dedicate
one chemotherapy treatment to block VEGF, we could then target ways to improve the
tumor’s oxygen metabolism.
Tumors cannot grow or spread without VEGF. By enhancing the body’s ability to carry
oxygen and employing other cancer-killing methods simultaneously, Envita is creating
new approaches to eliminate cancer and the processes that allow for their development
and growth. One secret is the ability to create an environment that is unwelcome to
stage 4 cancer cells.
And there is more good news, now that we know that precarious blood cells are an
excellent way to target cancers. Released VEGF binds to the endothelial cells of nearby
vessels, and subsequently, they begin to break up and grow in the direction of the tumor
in an effort to bring new vessels to feed it. These inferior vessels are relatively easy to
detect through photodynamic protocols, which means they can be isolated and attacked
while simultaneously strengthening healthy vessels throughout the body.
Research shows that VEGF is connected with a series of tumor types, including breast,
ovarian, cervical, esophageal, lung, and cervical cancer, as well as glioblastoma
multiforme and renal cell carcinoma. It would seem that VEGF emissions may also
hinder the immune system’s ability to react and fight off the tumor - regularly occurring
in stage 4 cancers.
One thing to keep in mind is that the immune system is the first and last defense against
stage 4 cancer. More than 90 percent of all cancer patients die because of metastasis, a
critical component for stage 4 cancer – the very process by which cancer cells can
spread into the blood supply and be dispersed throughout the body. Sadly, many
patients believe their cancer had been eradicated, only to discover later about dormant
metastasis and why cancer comes back often at stage 4. For this reason, it is
imperative to correct the body’s metabolism for oxygen and put a stop to angiogenesis.

4. For more information and articles on stage 4 cancer treatments, contact or visit us at
Envita’s website. If you know anyone who has been diagnosed with cancer, please
forward this article to them. We welcome you to contact us with questions and invite you
to watch informative videos. You can also visit our PPMR section to learn more about
the power of Envita’s personalized medicine (link to Envita PPMR page) for stage 4
cancer (link Envita cancer page) and chronic diseases. It is important information that
may save lives. Education is the best prescription.
Envita’s Comprehensive Smart Oncology uses the foremost of oncology in combination
with aggressive natural therapies to help a patient reach better health.
References:
*Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , <
http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer <
http://en.wikipedia.org/wiki/Stage-4_cancer#Systems_of_staging > * Vascular
endothelial growth factor
<http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov
<http://www.healthreform.gov/reports/fightingcancer/index.html>*American Cancer
Society
<http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu
ment/acspc-029771.pdf>